Source: GlobalData, Pharma Intelligence Center, [Accessed 24th April 2017]
Go deeper with GlobalData
Figure 1 displays the sales profiles of the top ten products in atrial fibrillation and the global value. The majority of the products shown maintain constant sales or slowly increase or decrease over the eight years. Xarelto, however, is predicted to increase at a much higher rate. This growth gives way to a large global growth.
Figure 2 shows the global total growth of the products. This growth has been compared to the growth of Xarelto. Figure 2 shows that the majority of growth in product sales (98.89%) for atrial fibrillation is from Xarelto. However, other products are increasing and decreasing during this period.
See Also:
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
